David Lamond, a former board member of IRulya Therapeutics, Inc., has filed a Form 144 to sell shares of the company. This filing, dated November 5, 2026, signifies a notable transaction in the biotech sector, particularly as Lamond is associated with the Blue Devil Trust, which is set to benefit from the sale.

Background

IRulya Therapeutics, Inc. operates within the biological products sector, specifically focusing on products that do not include diagnostic substances. The company, which was formerly known as Quince Therapeutics, Inc., underwent a name change on August 1, 2022. The firm is incorporated in Delaware and has its business address at 101 College Street, Suite 210, New Haven, CT.

What the Filing Says

The SEC filing indicates that Lamond intends to sell 3,471 shares of common stock, with an aggregate market value of approximately $103,534. The shares were acquired through open market transactions from Quince Therapeutics, now IRulya, between May 15, 2020, and December 14, 2023. The filing also notes that the sale is executed under the auspices of Merrill Lynch.

Impact

This transaction may affect various stakeholders, including IRulya Therapeutics and its investors. As a former board member, Lamond's actions could influence market perceptions of the company, especially amid ongoing changes in the biotech industry. The sale reflects broader trends in executive stock sales where insiders liquidate holdings, often signaling confidence or strategic repositioning.

What's Next

The filing does not say what happens next regarding the shares or any further actions from Lamond or the Blue Devil Trust.